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Summary
 
The genetic origins of CD8
 
1
 
 T cell–recognized unique antigens to which mice respond when
immunized with syngeneic tumor cells are unknown. The ultraviolet light-induced murine tu-
mor 8101 expresses an H-2K
 
b
 
-restricted immunodominant antigen, A, that induces cytolytic
CD8
 
1
 
 T cells in vivo A
 
1
 
 8101 cells are rejected by naive mice while A
 
2
 
 8101 tumor cells grow.
To identify the antigen H-2K
 
b
 
 molecules were immunoprecipitated from A
 
1
 
 8101 cells and
peptides were eluted by acid. The sensitizing peptide was isolated by sequential reverse-phase
HPLC and sequenced using microcapillary HPLC-triple quadruple mass spectrometry. The
peptide, SNFVFAGI, matched the sequence of the DEAD box protein p68 RNA helicase ex-
cept for a single amino acid substitution, caused by a single nucleotide change. This mutation
was somatic since fibroblasts from the mouse of tumor origin expressed the wild-type se-
quence. The amino acid substitution created an anchor for binding of the mutant peptide to
H-2K
 
b
 
. Our results are consistent with mutant p68 being responsible for rejection of the tu-
mor. Several functions of p68, which include nucleolar assembly and inhibition of DNA un-
winding, may be mediated through its IQ domain, which was altered by the mutation. This is
the first description of a somatic tumor–specific mutation in the coding region of a nucleic acid
helicase.
 
O
 
ne of the oldest, most important and yet unresolved
questions in tumor immunology is the nature of unique,
or individually distinct, tumor antigens to which mice re-
spond when immunized with tumor cells. Classical experi-
ments (1, 2) showed that mice immunized with tumor cell
lines rejected subsequent tumor cell transplants effectively,
when the same tumor cell line was used for immunization
and for challenge. Even cell lines of the same histologic type
and induced by the same carcinogen, did not induce cross-
protection (3). Shared cytolytic T cell–recognized antigens
have been identified on experimental as well as on human
tumors (4–9) and can, after active immunization, provide
transient protection in experimental models when the dose
of tumor cells used for challenge is small and the interval
between immunization and challenge is short (10, 11, for
review see reference 12). However, unique antigens pro-
vide strong and long-lived immunological protection
against transplantation of the same experimentally induced
cancer after active immunization with cancer cells (3),
whereas shared or crossreactive antigens do not. For exam-
ple the shared tumor antigen P1A (4) is expressed by multi-
ple tumor lines as determined by Northern blots and by
sensitivity to lysis by P1A-specific CTL. Even though this
antigen induces crossreactive T cells that are cytolytic for
multiple tumor lineages (13), protection is not provided by
this shared antigen but by unique antigens (13).
Oncogenes such as ras and suppressor genes such as p53
can encode tumor antigens (14–18) but these antigens ap-
pear to be different from those which cause tumor rejec-
tion after immunization with tumor cells (19). A unique T
cell–recognized antigen was found to be caused by a muta-
tion in the ribosomal gene L9 (20). While lymph node cells
specific for this antigen allowed SCID mice to reject a tu-
mor challenge, it remains unknown whether this antigen is
the natural rejection antigen of the tumor, particularly be-
cause progressor variants retained the antigen (20). Never-
theless, the availability of autologous normal and malignant
controls yielded the first unequivocal evidence that a
 
P. Dubey and R.C. Hendrickson contributed equally to this paper.
This work was presented in abstract form at the FASEB meeting. June
1996. 
 
FASEB J.
 
 10:A1437 (
 
Abstr.
 
).
  
696
 
Tumor-specific CD8
 
1
 
 CTL Recognize a Somatic Mutation in p68 Helicase
 
unique T cell–recognized antigen is caused by a somatic
mutation and thus is tumor-specific. Mutant L9 encodes a
peptide recognized by CD4
 
1
 
 T cells. However, in experi-
mental tumor systems, CD8
 
1
 
 
 
T cells are required for tumor
rejection (21, see reference 12 for review), so antigens rec-
ognized by these T cells are prime candidates for rejection
antigens. The genetic origins of several CD8
 
1
 
 cytolytic T
cell–recognized unique tumor-specific antigens have been
identified on human tumors (22–25); however not all
unique antigens recognized by CD8
 
1
 
 cytolytic T cells may
be capable of eliciting tumor rejection, and the functional
significance of these human antigens in tumor rejection is
unclear. The relevance of unique antigens for tumor rejec-
tion can be more readily studied in experimental systems
than in human systems. Earlier studies in experimental sys-
tems have shown that mutagen treatment of cancer cells in
vitro can result in variant tumor cells that are rejected by
normal hosts and also induces mutations that encode CD8
 
1
 
T cell–recognized antigens (26, 27). However, the genetic
origins of unique antigens not caused by such manipula-
tions on experimental tumors remained unknown. An in-
teresting genetic alteration consisting of three consecutive
nucleotide substitutions was reported to lead to a CTL-
defined antigen on the murine 3LL tumor (28); but, this
study and others (29, 30) lacked autologous controls. There-
fore germline mutations could not be excluded.
In this study, we have determined the genetic origin of a
unique CD8
 
1
 
 T cell–recognized, immunodominant anti-
gen on a UV-induced regressor tumor, for which autolo-
gous controls are available. Expression of this antigen is
correlated with tumor rejection, since progressor variants of
this tumor do not express the antigen. We show that the
antigen results from a somatic mutation which generates a
single amino acid change in the murine p68 RNA helicase
protein. This is also the first identification of a tumor-spe-
cific mutation in the coding region of a member of the
family of DEAD-box proteins of putative RNA helicases.
 
Materials and Methods
 
Mice.
 
Female C57BL/6 (H-2
 
b
 
) mice, 5–6 wk old, were pur-
chased from the Frederick Cancer Research Facility (Bethesda,
MD). C57BL/6 nu/nu (H-2
 
b
 
) mice were purchased from the
Jackson Laboratory (Bar Harbor, ME). Mice were maintained at
the University of Chicago in a pathogen-free barrier facility, and
fed autoclaved food and acidified sterile water.
 
Cell Lines.
 
The 8101 tumor was induced in our laboratory by
chronic ultraviolet light irradiation of C57BL/6 mice, three times
a week, as described (31). Tumor fragments were placed in vitro
to establish a cell line. The heart and lungs of the mouse were
harvested and chopped into fragments which were frozen in liq-
uid nitrogen, and also adapted to in vitro culture to generate a heart-
lung fibroblast (HLF)
 
1
 
 cell line. TAP-deficient RMA-S (H-2
 
b
 
) (32)
cells were used as targets after exogenous loading of peptides.
RMA-S and RMA (32) cells were a gift of Dr. J.A. Bluestone
(University of Chicago, IL). The BPV series of H-2
 
b
 
 UV-induced
tumors is a gift of Mr. Vijay Sreedhar and Dr. Margaret Kripke (Uni-
versity of Texas, M.D. Anderson Cancer Center, Houston, TX).
Cytolytic T cell lines and clones were generated as described (31).
 
Purification of Sensitizing Activity.
 
Tumor cells were expanded
in Nunc 10-chamber cell factories (Nunc, Thousand Oaks, CA),
detached with trypsin-EDTA, washed once with PBS, quick-fro-
zen as cell pellets and stored at 
 
2
 
80
 
8
 
C in polypropylene tubes.
To reduce peptide loss glass pipettes and polypropylene tubes
were used throughout the purification procedure. A batch of 10
 
10
 
cells was thawed, resuspended in lysis buffer (33) and rotated for
4–6 h at 4
 
8
 
C. The lysate was centrifuged at 3,500 
 
g
 
 for 30 min, and
the supernatant was rotated with 15–20 mg of purified mono-
clonal anti-H2-K
 
b
 
 Y-3 antibody coupled to protein A-Sepharose
(Pharmacia, Uppsala, Sweden) for 4–6 h at 4
 
°
 
C, washed three
times with PBS and three times with ddH
 
2
 
O (200 
 
g
 
, for 5 min).
The antigen was eluted by vortexing the pelleted Sepharose with
3–4 ml of 0.2% TFA/H
 
2
 
O (vol/vol) for 15 min at room temper-
ature. The eluate was divided into four 5,000 mol wt cutoff filters
(Millipore UFC4LCC25; Marlborough, MA) and centrifuged for
five h at 3,500 
 
g
 
, 4
 
8
 
C . The filtrate was concentrated to near-dryness
by vacuum centrifugation, pooled into a final volume of 150–200 
 
m
 
l
in 0.2% TFA/H
 
2
 
O and stored at 
 
2
 
80
 
8
 
C in 1.5 ml polypropylene
microfuge tubes (Sarstedt
 
Ô
 
, Inc., Newton, NC).
 
51
 
Cr-release Assays.
 
Five thousand 
 
51
 
Cr-labeled targets were
incubated with various numbers of T cells in flexible 96-well
V-bottom microtiter plates (Dynatech, Chantilly, VA) for 4.5 h
as described (31). The percentage of specific lysis was calculated
by the formula: % cytolysis 
 
5
 
 [(experimental release-spontaneous
release)/(maximum release 
 
2
 
 spontaneous release)] 
 
3
 
 100. Spon-
taneous release was 
 
,
 
15% of total release. To test HPLC fractions
for sensitizing activity, RMA-S cells which had been pre-incu-
bated at room temperature for at least 12 h, were 
 
51
 
Cr labeled and
then added to 50 
 
m
 
l FCS in each well of a 96-well plate. These
cells were then incubated with aliquots of HPLC fractions for 1.5 h
at 37
 
8
 
C. T cells were added to each well in 50 
 
m
 
l CDMEM and
the mixture was incubated for an additional 4 h at 37
 
8
 
C.
 
Micropore HPLC Separation.
 
Peptide fractionation was con-
ducted on an Aquapore
 
 
 
18 column (2.1 mm 
 
3
 
 3 cm). The pep-
tide extract was concentrated to 200 
 
m
 
l, injected onto a narrow
bore C18 column, and eluted with a 55-min binary gradient in-
creasing from 0–60% B at the rate of 3% B for the first 5 min,
then 0.9% B for the next 50 min. (Solvent A 
 
5
 
 0.1% heptafluo-
robutyric acid (HFBA) in NANOpure water; solvent B 
 
5
 
 0.085%
HFBA in 60% acetonitrile; flow rate 200 
 
m
 
l/min). Fractions were
collected into polypropylene tubes (Sarstedt
 
Ô
 
 2 ml, Cat no.
72.692) at 1-min intervals and 0.3% of each fraction was tested
for activity. Active fractions 36 and 37 were individually rechro-
matographed on the same column using a shallower gradient and
TFA as the ionic modifier. The second dimension gradient in-
creased from 0–60% B at the rate of 5% B for the first 5 min, then
0.7% B for the next 50 min (Solvent A 
 
5
 
 0.1% TFA in NAN-
Opure water; solvent B 
 
5
 
 0.085% TFA in 60% acetonitrile; flow
rate 200 
 
m
 
l/min). Fractions were collected into polypropylene
tubes at 1-min intervals and 1.5% was tested for activity.
 
Identification of Candidate Peptide.
 
Candidate peptides were iden-
tified by combining mass spectrometry with a sensitive 
 
51
 
Cr-release
assay as described previously (33). 60% of the second dimension frac-
tion was loaded onto a C18 microcapillary HPLC column (100 
 
m
 
m
 
tography-mass spectrometry; MLTC, mixed-lymphocyte tumor cell cul-
ture; PEC, peritoneal exudate cell; PITC, phenylisothiocyanate; TAP,
transporter associated with antigen processing.
 
1
 
Abbreviations used in this paper:
 
 CAD, collision-activated dissociation;
CDMEM, complete DMEM; CRPMI, complete RPMI; HFBA, hep-
tafluorobutyric acid; HLF, heart-lung fibroblast; LC-MS, liquid chroma- 
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i.d. 
 
3
 
 25 cm) end-connected with a zero dead volume union to
two capillaries of internal diameter 25 
 
m
 
m and 40 
 
m
 
m. Peptides
were eluted with a 34-min gradient of 0-60% B (solvent A 
 
5
 
 0.1 M
acetic acid; solvent B 
 
5
 
 acetonitrile) at a flow rate of 1 
 
m
 
l/min.
One-fifth of the eluent was deposited into each well of a 96-well
microtiter plate containing 50 
 
m
 
l CRPMI while the remaining
four-fifths was directed into the mass spectrometer. The m/z ra-
tio of each peptide deposited in a particular well was recorded on
the mass spectrometer. Peptides in individual wells of the 96-well
plate were then tested for sensitizing activity. The ion abundance
of a particular peptide is manually correlated with the sensitizing
activity to identify the mass of the candidate peptide.
 
Sequence Analysis of the Tumor Antigen Candidate.
 
To determine
the sequence of the tumor antigen an aliquot from the remaining
40% of subfraction 36-19 was loaded onto a C18 microcapillary
column (75 
 
m
 
m i.d. 
 
3
 
 12 cm) and eluted with a 12-min gradient
(0–80% acetonitrile in 0.1 M acetic acid) directly into a triple
quadruple mass spectrometer (Finnigan MAT, TSQ7000) essen-
tially as described (34, 35). This instrument is equipped with an
electrospray ionization source that was operated with a coaxial
sheath (70% MeOH/H
 
2
 
O containing 0.12% acetic acid) flowing
at 1.5 
 
m
 
l/min. A negative potential of 4.6 kV was applied to the
heated capillary. Quadrupole one was set to pass a 2 mass unit
window centered on 854, the m/z value corresponding to the
(M 
 
1 
 
H)
 
1
 
1
 
 ions of the tumor antigen. Ions of this mass were trans-
mitted to quadrupole 2 where they suffered collision-activated
dissociation (CAD). The resulting fragments were mass analyzed
in quadrupole 3 to produce the CAD mass spectrum shown in
Fig. 6.
 
Manual Edman Degradation.
 
The mixture of peptides in an al-
iquot of HPLC fraction 36-19 was treated with 5 
 
m
 
l of 5% phe-
nyl isothiocyanate (PITC) in pyridine. The resulting solution was
overlaid with argon, vortexed, and incubated for 30 min at 45
 
8
 
C.
This sample was lyophilized to dryness, resuspended in 15 
 
m
 
l se-
quencing grade TFA, overlaid with argon and incubated for 10
min at 37
 
8
 
C. TFA was removed under vacuum and the residue
was dissolved in 5 
 
m
 
l H
 
2
 
O. The solution was vortexed, and ex-
tracted twice with 15 
 
m
 
l 
 
n
 
-butyl acetate. For analysis by mass
spectrometry, the aqueous layer was isolated, evaporated to dry-
ness and resuspended in 1 
 
m
 
l acetic acid and 19 
 
m
 
l H
 
2
 
O. This
modification removes the NH
 
2
 
-terminal amino acid from all pep-
tides present in the mixture.
 
Identification of the COOH-terminal Amino Acid by Coelution with
Synthetic Peptides.
 
An aliquot of the HPLC fraction containing
the tumor antigen 854 was mixed with an equimolar amount of
either synthetic peptide SNFVFAGL or SNFVFAGI and eluted
from a microcapillary HPLC column directly into the mass spec-
trometer using a gradient of 0.1 M acetic acid and acetonitrile in-
creasing at 2% per min. Mass spectra were acquired every 1.5 s
over the mass range 300–1,400. The ion abundance at m/z 854
was plotted as a function of elution time.
 
Synthesis and Purification of Synthetic Peptides.
 
Peptides SNFV-
FAGI and VTFVFAGX were synthesized and purified either at the
University of Virginia, or at the Oligopeptide Synthesis Facility at
the University of Chicago by the solid phase method using stan-
dard fmoc chemistry and purified by HPLC. Peptide SNFVSAGI
was synthesized and purified by Chiron Mimotopes (Raleigh, NC)
and HPLC purified.
 
Amplification and Sequencing of cDNA and Genomic DNA. PCR
primers specific for the murine p68 RNA helicase cDNA were
synthesized (IDT, Coralville, IA). 59 primer Hel1, 59-AATTAA-
GGTACCGGTCCTTGCCCTCGCAGCTCC-3 and 39 primer
Hel2A 59-CGAGATCTCTGCACTGCAGTCATTTCTG-39 am-
plify a 2.1-kb fragment that encompasses the coding region of the
murine p68 RNA helicase cDNA. The cDNA was amplified us-
ing RT-PCR with the following conditions: 1.25 mM MgCl2,
25 pM of each primer, 70 U RNAsin (Promega, Madison, WI),
250 mM of each nucleotide, 1 ml RNA, and 25 U M-MLV re-
verse transcriptase (New England Biolabs, Beverly, MA), in a
100-ml reaction. The mixture was incubated at 388C for 10 min
to synthesize the cDNA, and 948C for 5 min to inactivate the re-
verse transcriptase. 1 ml of Taq polymerase (Promega), was added
to the reaction and the 2.1-kb cDNA was amplified by PCR for
40 cycles at 948C for 1 min, 558C for 2 min, 728C for 3 min fol-
lowed by a 5-min final extension at 728C. The PCR product was
cloned into the vector pcDNA3 (Invitrogen, San Diego, CA) us-
ing the KpnI site in the 59 primer, and the BglII site in the 39
primer. The subclones were sequenced using the Sequenase kit
(Amersham, Arlington Heights, IL). A 465-bp PCR product in-
cluding the region of the putative mutation was isolated from
8101 HLF genomic DNA and 8101-PRO genomic DNA using the
same PCR conditions and the internal 59 primer Hel1A 59-CGG-
GGTACCACTCTGCAGGCAAAAGGGGTGGATT-39. The
PCR products were sequenced using the fmol sequencing system
(Promega). Total RNA was isolated using either guanidinium
isothiocyanate, or by using the TRIÔ reagent (Molecular Re-
search Center, Inc., Cincinnati, OH). Total RNA from 8101-
RE was passed over an oligo (dT) cellulose column to isolate poly
(A)1 mRNA. Genomic DNA was isolated using the ONCOR
non-organic DNA isolation kit (ONCOR, Gaithersburg, MD).
Results
Expression of the CD81 T Cell–recognized A Antigen on the
8101 Tumor Correlates with Tumor Rejection by Naive Mice.
8101 was the first tumor isolated from a group of C57BL/6
mice that received chronic UV-irradiation. The tumor
arose on the back of the mouse after 11 mo of irradiation.
At this time the mouse was 14 mo old. As usually observed
for UV-induced tumors, 8101 readily adapted to culture
and the primary culture was cloned to study the antigenic
diversity of the cells that adapted. CD81 cytotoxic T lympho-
cyte (CTL) clones were generated from mixed lymphocyte
tumor cell cultures (MLTCs) of spleen cells from mice im-
munized by i.p. injection of live uncloned tumor cells. The
resulting T cell clones identified two types of tumor cell
clones: one which expressed two antigens designated A and
B, and a second that only expressed the B antigen. The pa-
rental uncloned cell line, designated 8101-PAR, expressed
both antigens and was lysed by anti-A as well as anti-B
CTL clones (Fig 1, A and B). The anti-A (Fig. 1 A) and
anti-B (Fig. 1 B) CTL clones lysed only 8101 lineage tu-
mor cells and did not lyse autochthonous normal fibro-
blasts, or RMA cells. We injected the original uncloned
8101-PAR tumor cell line and 8101 A1B1 and 8101
A2B1 clones into C57BL/6 nude mice to generate tumor
fragments. The developing tumors were transplanted as frag-
ments into naive normal C57BL/6 mice. Table 1 shows
that tumors derived from the A1 clone were regularly re-
jected and thus were designated 8101-RE. Tumors derived
from the A2 clone grew progressively and were therefore
designated as 8101-PRO. These results strongly suggested698 Tumor-specific CD81 CTL Recognize a Somatic Mutation in p68 Helicase
that the expression of the A antigen correlated with rejec-
tion of the A1 tumor in naive mice, and that absence of the
A antigen led to progressive tumor growth. The B antigen
was expressed on all 8101 lineage tumors but not other
C57BL/6 UV tumors (Fig. 2 B), indicating that the 8101-
RE and 8101-PRO tumors were of the same clonal origin.
The parental cell line 8101-PAR which, as suggested by
clonal analysis, contained A1 as well as A2 tumor cells,
grew progressively when fragments were transplanted into
naive normal mice. The reisolated tumor cells when re-
adapted to culture were resistant to anti-A CTL, unlike the
8101-PAR tumor cells which had been used for the chal-
lenge (Fig. 1 A). These data indicated that normal mice
usually selected against expression of the A antigen. Only
one re-isolated tumor still showed sensitivity to lysis by
anti-A CTL; this tumor may have been able to grow as A1
because of the simultaneous challenge with A2B1 progres-
sor tumor cells which were also present in the 8101-PAR
tumor. These A2B1 tumor cells may have prevented the
establishment of an effective anti-A response. This sugges-
tion is in agreement with our previous observation that
progressor tumors can sometimes prevent an immune re-
sponse to highly antigenic tumor cells (36).
The A Antigen on the 8101-RE Tumor Is Unique, Immuno-
dominant, Kb-restricted, and a Powerful Sensitizer of Anti-A
Cytolytic T Cells. Since the expression of the A antigen
correlated with rejection of the tumor challenge, we further
characterized this antigen. Fig. 2 A shows that the anti-A
CTL clone recognized only 8101-RE cells, but not any of 5
other UV-induced tumors of C57BL/6 origin that were
tested. This result suggests that the 8101 A antigen is
unique, i.e., individually distinct, for the 8101 tumor, as
has been previously shown in our laboratory for other UV-
induced tumors (31). To determine how commonly this
antigen is recognized in vivo, four mice were injected re-
peatedly with 8101-RE cells, which express both the A and
the B antigen. Peritoneal exudate cells (PEC) were isolated
and directly tested for lytic activity (Fig. 3). PECs from all
four mice lysed the A1B1 8101-RE tumor cells but not the
A2B1 8101-PRO tumor cells, suggesting that the A anti-
Figure 1. Antigenic differences between 8101 tumor cell clones. The B
antigen is expressed on all three lines derived from the 8101 tumor while
the A antigen is expressed on the uncloned 8101-PAR tumor cells, and
on some of the 8101 tumor cell clones. Autologous non-malignant fibro-
blasts, 8101-HLF and a syngeneic lymphoma cell RMA are not lysed by
either the anti-A or anti-B CTL clone. Target cells were tested in a 51Cr-
release assay for lysis using the anti-A CTL ( A) and the anti-B CTL (B) as
effector cells.
Figure 2. The anti-A and anti-B CTL clones are uniquely specific for the
8101 tumor lineage. The anti-A CTL clone ( A) lyses only the 8101-RE
tumor cell but not five other C57BL/6-derived UV-induced tumors, or
the H-2b haplotype lymphoma RMA. The anti-B CTL clone (B) lyses
the 8101-RE and the 8101-PRO tumor cells, but not three other
C57BL/6-derived UV-induced tumors, or RMA cells. Targets were
tested for lysis in a 51Cr-release assay.
Table 1. Growth In Vivo of Uncloned 8101 Tumor and 8101 
Tumor Clones
Tumor incidence*
Phenotype‡ Tumor
Expt
no.
Nude
mice
Normal
mice§
Reisolate
phenotype
A1B1 8101-PAR 1 1/1 15/15 ND
2 1/1 6/6 2/3 A2, 1/3 A1
3 1/1 3/3 3/3 A2
A1B1 8101-RE 1 1/1 0/4 NA
2 1/1 0/4 NA
A2B1 8101-PRO 1 1/1 4/4 ND
2 1/1 4/4 ND
*Number of mice with progressively growing tumors per number chal-
lenged. Mice were followed for at least 4 wk, or until they became
moribund at which point they were killed.
‡The phenotype, A1 or B1 is defined by the recognition of the tumor
cells in vitro by an anti-A CTL clone or anti-B CTL clone. The pheno-
type A2 is defined by the lack of recognition of the reisolated tumor
cells in vitro by an anti-A CTL clone.
§C57BL/6 mice were injected subcutaneously with C57BL/6 nude
mouse tumor fragments using a trocar, except in experiment 1 (8101-PAR),
where (B6C3) F1 mice were injected with the tumor fragments from a
C3H/HeN nude mouse. Nude mice were always injected last as viability
control. In experiment 1, mice were injected with 10 3 1 mm3 fragments.
In experiment 2 and 3 mice were injected with 3 3 1 mm3 fragments.
NA, not applicable. ND, not done.699 Dubey et al.
gen is regularly recognized and is immunodominant. Lysis
by the anti-A CTL clone was inhibited by an anti-Kb but
not an anti-Db antibody indicating that the A antigen was
H-2Kb restricted (data not shown). To examine the possi-
bility of biochemical identification of the A antigen, we de-
termined whether peptides eluted from the H-2Kb mole-
cules immunoprecipitated from 8101-RE cells would sensitize
RMA-S cells to become a specific target for lysis by anti-A
CTL. As little as 0.2% of an immunoprecipitate from 1 3
109 8101-RE cells contained sensitizing activity (data not
shown).
Isolation and Sequencing of the A Antigen Peptide. To iso-
late the naturally processed A antigen peptide, we immu-
noprecipitated the H-2Kb molecules from 5 3 1010 8101-RE
tumor cells. Associated peptides were eluted from the
MHC class I molecule with acid, and separated from high
molecular mass proteins by filtration through a 5-kD mo-
lecular mass cutoff membrane. The unfractionated peptide
extract sensitized RMA-S cells for lysis by the anti-A CTL
clone (data not shown). The peptide extract was concen-
trated and then fractionated by reverse-phase high-perfor-
mance liquid chromatography (RP-HPLC) using heptaflu-
orobutyric acid (HFBA) as the ionic modifier. Aliquots
from individual fractions were tested. Only two fractions,
36 and 37, sensitized RMA-S cells for lysis by an anti-A
CTL clone (Fig. 4 A). Active fractions 36 and 37 were in-
dividually rechromatographed over the same HPLC col-
umn, using a shallower gradient and TFA as the ionic mod-
ifier. A peptide in subfraction 36-19, 36-20 (Fig. 4 B), and
37-19 (Fig. 4 C) sensitized RMA-S cells for lysis by the
anti-A CTL clone. However, each subfraction contained
more than 100 peptides, too many to sequence with the
available material. Therefore, to identify the mass of the A
antigen in these mixtures, 60% of each HPLC subfraction
was analyzed separately (the remaining 40% was set aside
for further analysis) with an on-line microcapillary column
effluent splitter, as described previously (33). Four-fifths of
the effluent is directed into the mass spectrometer for anal-
ysis, while the other one-fifth is simultaneously deposited
into a 96-well plate for analysis of sensitizing activity. Since
both pieces of data are acquired as a function of time, the
ion abundance corresponding to a particular peptide can be
correlated with the biological activity. The microcapillary
split of subfraction 36-19 and 37-19 yielded activity (Fig. 5,
A and B, respectively) but no sensitizing activity was ob-
served from the peptides in subfraction 36-20 (data not
shown). Therefore, the candidate peptide antigen should
be present in wells 41 and 44, absent in neighboring wells
of both microcapillary splits, and either absent or greatly re-
duced in abundance in subfraction 36-20 where no sensi-
tizing activity was observed. Only a single peptide, that
with m/z 854, fulfilled all the above criteria.
An aliquot of the remaining 40% of subfraction 36-19
was used to sequence the candidate peptide by mass spec-
Figure 3. The A antigen is immunodominant in vivo. Each panel shows
a different C57BL/6 mouse immunized i.p. on day 0, 3, 6, and 9 with
2–5 3 106 A1B1 8101-RE tumor cells. The PEC were harvested on day
11 and directly tested in a 51Cr-release assay for lytic activity. Only the
A1B1 8101-RE cells, but not the A2B1 8101-PRO cells, or RMA cells
are lysed by the PEC.
Figure 4. Sequential HPLC separation of sensitizing peptides eluted from
the H2-Kb molecule of 8101-RE cells. A shows the results of the first-
dimension microbore HPLC separation of peptides eluted from 5 3 1010
8101-RE cells, using HFBA as the ionic modifier. A portion (0.3%) of
each fraction was loaded onto RMA-S cells and tested for lysis by the
anti-A CTL clone in a 51Cr-release assay. Sensitizing fractions 36 and 37
were subfractionated on the same microbore column using TFA as the
ionic modifier (B and C). RMA-S cells were loaded with 1.5% of each
subfraction and tested for lysis by the anti-A CTL clone. The E/T ratio
was 5:1. Peptide loaded RMA-S cell with CTL (solid bars) or without
CTL (hatched bars) as toxicity controls are shown in A. Toxicity controls
were not done in B and C.700 Tumor-specific CD81 CTL Recognize a Somatic Mutation in p68 Helicase
trometry. Shown in Fig. 6 A is the CAD mass spectra on
the (M1H)11 ions at m/z 854. The observed fragmentation
is sufficient to specify the sequence of residues 3-8 as FVF-
AGX, where X is leucine or isoleucine, and residues 1-2 as
either SN or NS. Leucine and isoleucine, two amino acids
of identical mass, cannot be differentiated on a triple qua-
drupole instrument. To determine the identity and order of
the first two amino acids in the epitope, peptides in an ali-
quot of subfraction 36-19 were subjected to a single cycle
of Edman degradation and then analyzed by microcapillary
liquid chromatography-mass spectrometry (LC-MS). In the
resulting mass spectra the (M1H)11 ion for the antigen was
observed at m/z 767, a shift of 87 daltons corresponding to
the amino acid serine. The CAD mass spectra recorded on
the (M1H)11 ions at m/z 767 confirmed the seven-residue
sequence, NFVFAGX. So, the complete amino acid sequence
was SNFVFAGX.
To specify the COOH-terminal residue in the epitope as
either Leu or Ile, we performed coelution experiments in
Figure 5. Identification of the tumor antigen candidate peptide. The
abundance of the peptide at m/z 854 correlates with the biological activity
in the microcapillary HPLC split of subfractions 36-19 ( A) and 37-19 (B).
Figure 6. Structural characterization of the tumor epitope. (A) CAD mass spectrum recorded from the (M1H)11 ions (m/z 854) of the tumor antigen.
(B) CAD mass spectrum recorded on (M1H)11 ions (m/z 767) from the tumor antigen after a single round of Edman degradation. The ions observed in
each spectra are underlined. (C) Results of coelution experiments in which synthetic peptides SNFVFAGL or SNFVFAGI were added to the biologically
active subfraction 37-19 containing the tumor antigen. (D) synthetic peptides SNFVFAGI and VTFVFAGX (X 5 L or I) were loaded onto RMA-S cells
in the indicated concentrations, and tested for lysis by the anti-A CTL clone. The E/T ratio was 5:1. SNFVFAGI is specifically recognized by the anti-A
CTL clone.701 Dubey et al.
which aliquots of the biologically active HPLC fraction 37-19
were analyzed by microcapillary LC-MS before and after
being doped with synthetic peptides SNFVFAGI or SN-
FVFAGL. Results of this experiment are shown in Fig. 6 C.
Analysis of the mixture doped with SNFVFAGL showed
two discrete peptide components at m/z 854. In contrast,
the mixture doped with SNFVFAGI showed only a single
component at m/z 854. Therefore, coelution of SNFVF-
AGI with the tumor antigen confirms that the COOH-ter-
minal residue in the epitope is isoleucine. The synthetic
peptide SNFVFAGI sensitized RMA-S cells for lysis by the
anti-A CTL clone, but control peptide VTFVFAGX did
not (Fig. 6 D), nor did two additional H-2Kb-binding pep-
tides tested in a separate experiment (data not shown).
Half-maximal lysis of peptide loaded RMA-S cells oc-
curred at 2 pmol peptide.
The Peptide SNFVFAGI Originates from a Somatic Tumor-
specific Point Mutation in the p68 RNA Helicase Gene. The pep-
tide SNFVFAGI was analyzed for homology with known
protein sequences using the BLAST program (37). The tu-
mor-derived peptide matched the murine p68 RNA heli-
case sequence (38) except that the former had phenylala-
nine instead of serine at position five, suggesting that the
tumor peptide might be encoded by a mutant p68 RNA
helicase gene in the tumor cells. To confirm this hypothesis
cDNA was synthesized and amplified from tumor cell
(8101-RE) mRNA by RT-PCR and primers specific for
the p68 RNA helicase. The amplified 2.1-kb product
pooled from three independent RT-PCR reactions was
cloned into the vector pcDNA3. Six cDNA clones were
sequenced using primers for the 39 end of the insert, that
included the region of the putative mutation. Two of the
six clones were identical to the wild-type sequence of mu-
rine p68 RNA (38) helicase while the other four had a T
instead of a C at the nucleotide position 1812. This nucle-
otide substitution resulted in a change to phenylalanine
from serine at amino acid 551 (Fig. 7). The C to T transi-
tion, which occurred at a dipyrimidine site, is a commonly
observed UV-induced mutation (39).
The sequence data derived from the 8101-RE tumor
cells suggests that the cloned tumor cell line is heterozygous
for the mutation, and expresses both the wild-type and
mutant forms of murine p68 RNA helicase. Sequencing of
six cDNA clones from 8101-HLF (Fig. 7), and PCR se-
quencing of amplified genomic p68 DNA from autochtho-
nous heart-lung fibroblasts and from 8101-PRO tumor
cells (data not shown) revealed only wild-type sequences.
These data indicated that the mutant peptide had been gen-
erated by a somatic mutation that was absent in the 8101-
PRO tumor cells and was consistent with our finding that
the PRO tumor and HLF cells were resistant to lysis by the
anti-A CTL clone (Fig. 1).
Figure 7. The mutant p68 RNA helicase peptide was generated by a sin-
gle amino acid substitution that resulted from a single nucleotide change
in 8101-RE. cDNA sequences of murine p68 RNA helicase are com-
pared with p68 sequences of 8101-RE in the region of the mutation. Se-
quence identity is indicated by ---. RE: sequences from 4/6 cDNA
clones from 8101-RE. HLF: sequence from 6 cDNA clones from 8101-
HLF. WT: published murine p68 RNA helicase cDNA sequence (refer-
ence 38). A single nucleotide substitution of C®T at nucleotide 1812
was found in the 8101-RE tumor, but not in 8101-HLF.
Figure 8. The mutant p68 peptide sensitizes RMA-S cells for lysis by the
anti-A CTL clone, and stabilizes MHC class I on the cell surface, but the
corresponding wild-type peptide does not. The mutant peptide SNFVF-
AGI and the wild-type peptide SNFVSAGI were loaded onto RMA-S
cells in the indicated amounts. (A) the loaded cells were tested for lysis by
the anti-A CTL clone in a 51Cr-release assay at an E/T ratio of 2:1. (B)
loaded cells were analyzed for cell surface expression of H-2Kb using fluo-
rescence activated cell sorter analysis, by indirect immunofluorescence with
the monoclonal anti-H2-Kb antibody Y-3 and a polyclonal goat anti–
mouse IgG conjugated to fluorescein isothiocyanate as a second step. Per-
cent stabilization of H-2Kb was calculated by subtracting the amount of
H-2Kb present on RMA-S cells shifted to 378C without added peptide,
from the amount of H-2Kb present on RMA-S cells shifted to 378C in
the presence of peptide, and dividing by the amount of H-2Kb present on
RMA-S cells which had been kept at room temperature throughout the
experiment.702 Tumor-specific CD81 CTL Recognize a Somatic Mutation in p68 Helicase
The H-2Kb-binding motif (40) predicts that, first, the
anchor residue for binding to the molecule is at position
five of the peptide, and is an aromatic residue, either phe-
nylalanine or tyrosine, and second, that position eight of
the peptide is either a leucine or isoleucine. This sequence
motif predicts that the normal homologue of the A antigen
peptide, which has serine at position five, would not bind
to H-2Kb. Consistent with this prediction, we found that
the wild-type peptide SNFVSAGI, in contrast to the mu-
tant peptide SNFVFAGI, neither sensitized RMA-S cells
for lysis by the anti-A CTL clone (Fig. 8 A) nor bound ef-
fectively to H2-Kb as measured by stabilization of H2-Kb
on the surface of RMA-S cells (Fig. 8 B).
We found that three of four mice immunized repeatedly
with 8101-RE cells intraperitoneally generated peritoneal
exudate cells in vivo that recognized the mutant peptide
loaded onto RMA-S cells (data not shown). In addition,
the spleens from all 4 of these mice, after in vitro restimula-
tion with the 8101-RE tumor, recognized the mutant p68
peptide (data not shown). These data confirm that SNFVF-
AGI indeed represents the immunodominant antigen of
the regressor tumor 8101-RE.
Discussion
In this study, we have identified the genetic origin of the
immunodominant A antigen of the ultraviolet light-induced
regressor tumor 8101-RE. The antigenic peptide is SNFV-
FAGI. It is generated by a point mutation in the murine
p68 RNA helicase gene, which changed a C to T, resulting
in an amino acid substitution to phenylalanine from serine.
The amino acid change also generated an anchor for bind-
ing of the peptide to the restricting molecule for the anti-
gen, H-2Kb. Although other still unknown 8101-RE genes
might also encode the same peptide, the fact that 8101-
PRO tumor cells which are not lysed by anti-A CTL also
do not have the mutant p68, indicates that mutant p68 en-
codes the mutant peptide. In addition, the mutation is
likely to have occurred in vivo since it was found in DNA
of primary tumor cell cultures and thus is unlikely to be an
artifact of in vitro culture. The mutation is of somatic tumor-
specific origin, rather than representing a genetic polymor-
phism of germline origin, since autochthonous nonmalignant
fibroblasts from the mouse which gave rise to the tumor
did not harbor the mutation. Several unique CTL-recog-
nized antigens have now been identified in human tumors
and shown to be due to tumor-specific somatic mutations
(22–25). However, this is the first identification of a unique
tumor-specific CTL antigen in the murine system. We will
now be able to evaluate the role of such an antigen in tu-
mor rejection.
To our knowledge, our finding represents the first dem-
onstration of a tumor-specific somatic mutation in the cod-
ing region of a member of the DEAD-box protein family
of putative RNA helicases (41). A translocation into the 59
non-coding region of a human putative RNA helicase has
been reported earlier (42). In addition, two inherited syn-
dromes in man, Bloom’s syndrome (43) and Werner’s syn-
drome (44), both of which show a predisposition to cancer
development, have recently been discovered to be linked
to DNA helicases. The p68 RNA helicase protein was first
identified by Lane and Hoeffler in 1980 (45), because of its
immunological cross-reactivity with an antibody that rec-
ognized the SV40 large T antigen. These investigators at-
tempted to find a homologue of T antigen by searching for
antibody-recognized determinants that cellular proteins
might share with the T antigen (45). p68 is a nuclear pro-
tein (46), that was later discovered to be an RNA helicase
(47, 48).
The primary amino acid sequence of the murine p68
protein is shown in Fig. 9. The first eight boxed motifs
show the domains of homology of p68 with other DEAD
box proteins, which play a central role in cell growth in a
wide variety of organisms. p68 has been shown to undergo
dramatic changes in nuclear localization during telophase,
when it translocates from the nucleoplasma to the nucleoli
(49). In addition, a stretch of amino acids, called the IQ do-
main (50) is located within the 139 carboxy-terminal amino
acids that extend beyond the region of homology with
other DEAD box proteins, and which distinguishes p68 from
these proteins (41). This domain, which is also found in
molecules such as neurogranin and neuromodulin, is sub-
ject in vitro to calmodulin (CaM) binding and phosphory-
lation by protein kinase C (PKC) (50). Experimental evi-
dence suggests that CaM and/or PKC may regulate at least
some of the activity of p68 during the cell cycle, through
this domain (50). The mutation changes one of the two
serines in the IQ domain to a phenylalanine (thick box in
Fig. 9), but we do not yet know whether the mutation of S
to F affects the physiologic function or localization of the
protein. In addition to being an RNA helicase, p68 is also a
powerful inhibitor of DNA helicases (51). This activity is
quite similar to that of the p53 tumor suppressor gene
which also prevents DNA helicase activity (51). It has been
suggested that the general role of p53 is to safeguard the in-
tegrity of the genome by monitoring and stopping replica-
Figure 9. Predicted primary amino acid sequence of wild-type murine
p68 RNA helicase. The eight regions of homology to other DEAD-box
proteins are outlined by the thin box. The IQ domain, found at the
COOH-terminal end of the protein is outlined by the thick box. Within
this IQ box, the eight–amino acid stretch from which the mutant peptide
is derived is underlined. In the 8101-RE tumor, the second serine was
changed to a phenylalanine in this eight–amino acid stretch.703 Dubey et al.
tion when DNA is damaged (52), and it is possible that p68
may serve a similar function as a tumor suppressor gene.
Our study shows that the CD81 T cell–recognized A
antigen SNFVFAGI (a) is the immunodominant antigen of
the 8101-RE tumor, which induces a powerful CD81 T
cell response in vivo when whole cells are used for vaccina-
tion, (b) sensitizes target cells at picomolar amounts for lysis
by specific T cells and (c) is not expressed by the 8101-
PRO tumor. Conclusive evidence that this antigen leads to
rejection of the 8101-RE tumor would come from dem-
onstrating that expression of the A antigen after transfection
of 8101-PRO converts the progressor to a regressor phe-
notype, i.e., that the progressor tumor is rejected by naive
syngeneic mice after expression of the A antigen. We have
not yet been able to detect expression of the mutant p68
protein after transfection despite using various eukaryotic
expression vectors. It is possible that constitutive expression
of this protein, which is tightly regulated during cell cycle,
may be toxic to the cells. Nevertheless, the mutant p68
peptide is a strong candidate for a rejection antigen.
One critical question that bears investigation is whether
the proteins from which unique tumor antigens are derived
also play a role in the development of the malignant phe-
notype. The transformation of a cell from normal to malig-
nant requires multiple genetic mutations, and it is hypothe-
sized that each of these mutations confers a successive
growth advantage upon the cell, which ultimately leads to
malignancy (53). It is possible that the same mutations also
generate unique tumor antigens. Alternatively, the muta-
tions we observed may only generate the unique antigen
but play no additional role in the tumorigenic process.
Nevertheless, it is tempting to speculate on the role of p68
as a possible tumor suppressor gene which may be lost dur-
ing tumor progression. Since two human syndromes are as-
sociated with both increased incidence of malignancy and
defective helicase function (43, 44), it may be that p68
functions normally as a tumor suppressor, and loss of this
protein function would then be associated with the malig-
nant phenotype. Moreover, it is possible that the develop-
ment of the A antigen is associated with defective function,
and hence with the malignant phenotype. In contrast to the
situation for tumor suppressor genes, other antigens may be
mutant oncogenes which could be essential for maintaining
the malignant phenotype, and thus would be expected to
be retained by selection. These antigens may also serve as
markers for the stages of tumor progression, and would be
ideal targets for immunotherapy. Indeed, we have observed
both retained and lost antigens on UV-induced tumors (20,
21). Studying the genetic origins of unique tumor antigens
may identify genes that are functionally involved in malig-
nancy, but which may not be identified by traditional ap-
proaches such as searching for chromosomal translocations
or using subtractive libraries. Identifying the genetic origins
of unique antigens encoding tumor-specific mutations could
therefore contribute to a more complete understanding of
the malignant process.
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